|
1
|
Tang N, Song WX, Luo J, Haydon RC and He
TC: Osteosarcoma development and stem cell differentiation. Clin
Orthop Relat Res. 466:2114–2130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lv YF, Yan GN, Meng G, Zhang X and Guo QN:
Enhancer of zeste homolog 2 silencing inhibits tumor growth and
lung metastasis in osteosarcoma. Sci Rep. 5:129992015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Au SL, Wong CC, Lee JM, Wong CM and Ng IO:
EZH2-mediated H3K27me3 is involved in epigenetic repression of
deleted in liver cancer 1 in human cancers. PLoS One. 8:e682262013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Simon JA and Lange CA: Roles of the EZH2
histone methyl-transferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schlesinger Y, Straussman R, Keshet I,
Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E,
Reubinoff BE, et al: Polycomb-mediated methylation on Lys27 of
histone H3 pre-marks genes for de novo methylation in cancer. Nat
Genet. 39:232–236. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao R, Wang L, Wang H, Xia L,
Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Czermin B, Melfi R, McCabe D, Seitz V,
Imhof A and Pirrotta V: Drosophila enhancer of Zeste/ESC complexes
have a histone H3 methyltransferase activity that marks chromosomal
Polycomb sites. Cell. 111:185–196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li K, Chen MK, Situ J, Huang WT, Su ZL, He
D and Gao X: Role of co-expression of c-Myc, EZH2 and p27 in
prognosis of prostate cancer patients after surgery. Chin Med J
(Engl). 126:82–87. 2013.
|
|
11
|
Suvà ML, Riggi N, Janiszewska M,
Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino
D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem
cell maintenance. Cancer Res. 69:9211–9218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koh CM, Iwata T, Zheng Q, Bethel C,
Yegnasubramanian S and De Marzo AM: Myc enforces overexpression of
EZH2 in early prostatic neoplasia via transcriptional and
post-transcriptional mechanisms. Oncotarget. 2:669–683. 2011.
View Article : Google Scholar
|
|
13
|
Zhang X, Zhao X, Fiskus W, Lin J, Lwin T,
Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, et al: Coordinated
silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic
target of histone modification in aggressive B-Cell lymphomas.
Cancer Cell. 22:506–523. 2012. View Article : Google Scholar
|
|
14
|
Meyer N and Penn LZ: Reflecting on 25
years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuser-Abali G, Alptekin A and Cinar B:
Overexpression of MYC and EZH2 cooperates to epigenetically silence
MST1 expression. Epigenetics. 9:634–643. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dang CV, O'Donnell KA, Zeller KI, Nguyen
T, Osthus RC and Li F: The c-Myc target gene network. Semin Cancer
Biol. 16:253–264. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duncan R, Bazar L, Michelotti G, Tomonaga
T, Krutzsch H, Avigan M and Levens D: A sequence-specific,
single-strand binding protein activates the far upstream element of
c-myc and defines a new DNA-binding motif. Genes Dev. 8:465–480.
1994. View Article : Google Scholar
|
|
18
|
Zhang J and Chen QM: Far upstream element
binding protein 1: A commander of transcription, translation and
beyond. Oncogene. 32:2907–2916. 2013. View Article : Google Scholar
|
|
19
|
Matsushita K, Tomonaga T, Shimada H,
Shioya A, Higashi M, Matsubara H, Harigaya K, Nomura F, Libutti D,
Levens D, et al: An essential role of alternative splicing of c-myc
suppressor FUSE-binding protein-interacting repressor in
carcinogenesis. Cancer Res. 66:1409–1417. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zubaidah RM, Tan GS, Tan SB, Lim SG, Lin Q
and Chung MC: 2-D DIGE profiling of hepatocellular carcinoma
tissues identified isoforms of far upstream binding protein (FUBP)
as novel candidates in liver carcinogenesis. Proteomics.
8:5086–5096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dixit U, Liu Z, Pandey AK, Kothari R and
Pandey VN: Fuse binding protein antagonizes the transcription
activity of tumor suppressor protein p53. BMC Cancer. 14:9252014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dixit U, Pandey AK, Liu Z, Kumar S,
Neiditch MB, Klein KM and Pandey VN: FUSE binding protein 1
facilitates persistent hepatitis C virus replication in hepatoma
cells by regulating tumor suppressor p53. J Virol. 89:7905–7921.
2015. View Article : Google Scholar :
|
|
23
|
Zhang Z, Harris D and Pandey VN: The FUSE
binding protein is a cellular factor required for efficient
replication of hepatitis C virus. J Virol. 82:5761–5773. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chien HL, Liao CL and Lin YL: FUSE binding
protein 1 interacts with untranslated regions of Japanese
encephalitis virus RNA and negatively regulates viral replication.
J Virol. 85:4698–4706. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bettegowda C, Agrawal N, Jiao Y, Sausen M,
Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G,
et al: Mutations in CIC and FUBP1 contribute to human
oligodendroglioma. Science. 333:1453–1455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rabenhorst U, Beinoraviciute-Kellner R,
Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J,
Chung HJ, Levens DL, et al: Overexpression of the far upstream
element binding protein 1 in hepatocellular carcinoma is required
for tumor growth. Hepatology. 50:1121–1129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan JZ, Yan Y, Wang XX, Jiang Y and Xu HE:
EZH2: Biology, disease, and structure-based drug discovery. Acta
Pharmacol Sin. 35:161–174. 2014. View Article : Google Scholar :
|
|
28
|
Verma SK, Tian X, LaFrance LV, Duquenne C,
Suarez DP, Newlander KA, Romeril SP, Burgess JL, Grant SW, Brackley
JA, et al: Identification of potent, selective, cell-active
inhibitors of the histone lysine methyltransferase EZH2. ACS Med
Chem Lett. 3:1091–1096. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Amatangelo MD, Garipov A, Li H,
Conejo-Garcia JR, Speicher DW and Zhang R: Three-dimensional
culture sensitizes epithelial ovarian cancer cells to EZH2
methyltransferase inhibition. Cell Cycle. 12:2113–2119. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mizushima N, Yamamoto A, Matsui M,
Yoshimori T and Ohsumi Y: In vivo analysis of autophagy in response
to nutrient starvation using transgenic mice expressing a
fluorescent autophagosome marker. Mol Biol Cell. 15:1101–1111.
2004. View Article : Google Scholar :
|
|
31
|
Asanuma K, Tanida I, Shirato I, Ueno T,
Takahara H, Nishitani T, Kominami E and Tomino Y: MAP-LC3, a
promising autophagosomal marker, is processed during the
differentiation and recovery of podocytes from PAN nephrosis. FASEB
J. 17:1165–1167. 2003.PubMed/NCBI
|
|
32
|
Seglen PO and Gordon PB: 3-Methyladenine:
Specific inhibitor of autophagic/lysosomal protein degradation in
isolated rat hepatocytes. Proc Natl Acad Sci USA. 79:1889–1892.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Radulovi V, de Haan G and Klauke K:
Polycomb-group proteins in hematopoietic stem cell regulation and
hematopoietic neoplasms. Leukemia. 27:523–533. 2013. View Article : Google Scholar
|
|
34
|
Popovic R and Licht JD: Emerging
epigenetic targets and therapies in cancer medicine. Cancer Discov.
2:405–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao X, Lwin T, Zhang X, Huang A, Wang J,
Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E and Tao J:
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell
lymphoma survival and clonogenicity. Leukemia. 27:2341–2350. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu TP, Lo HL, Wei LS, Hsiao HH and Yang
PM: S-Adenosyl-L-methionine-competitive inhibitors of the histone
methyltransferase EZH2 induce autophagy and enhance drug
sensitivity in cancer cells. Anticancer Drugs. 26:139–147. 2015.
View Article : Google Scholar
|
|
37
|
Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu
H, Sun L, Zhang Y, Chen Y, Li R, et al: Integration of estrogen and
Wnt signaling circuits by the polycomb group protein EZH2 in breast
cancer cells. Mol Cell Biol. 27:5105–5119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sander S, Bullinger L, Klapproth K,
Fiedler K, Kestler HA, Barth TF, Möller P, Stilgenbauer S, Pollack
JR and Wirth T: MYC stimulates EZH2 expression by repression of its
negative regulator miR-26a. Blood. 112:4202–4212. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaur M and Cole MD: MYC acts via the PTEN
tumor suppressor to elicit autoregulation and genome-wide gene
repression by activation of the Ezh2 methyltransferase. Cancer Res.
73:695–705. 2013. View Article : Google Scholar :
|
|
40
|
Malz M, Weber A, Singer S, Riehmer V,
Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, et
al: Overexpression of far upstream element binding proteins: A
mechanism regulating proliferation and migration in liver cancer
cells. Hepatology. 50:1130–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Singer S, Malz M, Herpel E, Warth A,
Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, et
al: Coordinated expression of stathmin family members by far
upstream sequence element-binding protein-1 increases motility in
non-small cell lung cancer. Cancer Res. 69:2234–2243. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ferraro A, Boni T and Pintzas A: EZH2
regulates cofilin activity and colon cancer cell migration by
targeting ITGA2 gene. PLoS One. 9:e1152762014. View Article : Google Scholar : PubMed/NCBI
|
